To include your compound in the COVID-19 Resource Center, submit it here.

Pays to stay private

Why ADC Therapeutics chose to stay private with $200 million financing

While ADC Therapeutics S.A. has the hallmarks of a biotech ready for the public markets, the Swiss cancer company decided to stay private with its latest financing, citing the relative cost of capital.

The oversubscribed

Read the full 355 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers